These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
413 related articles for article (PubMed ID: 28895028)
1. Prevalence of QT interval prolonging drug-drug interactions (QT-DDIs) in psychiatry wards of tertiary care hospitals in Pakistan: a multicenter cross-sectional study. Khan Q; Ismail M; Haider I; Khan F Int J Clin Pharm; 2017 Dec; 39(6):1256-1264. PubMed ID: 28895028 [TBL] [Abstract][Full Text] [Related]
2. Frequency, characteristics and risk factors of QT interval prolonging drugs and drug-drug interactions in cancer patients: a multicenter study. Khan Q; Ismail M; Khan S BMC Pharmacol Toxicol; 2017 Dec; 18(1):75. PubMed ID: 29191244 [TBL] [Abstract][Full Text] [Related]
3. Prevalence of the risk factors for QT prolongation and associated drug-drug interactions in a cohort of medical inpatients. Khan Q; Ismail M; Haider I; Ali Z J Formos Med Assoc; 2019 Jan; 118(1 Pt 1):109-115. PubMed ID: 29458991 [TBL] [Abstract][Full Text] [Related]
4. Frequency, characteristics and nature of risk factors associated with use of QT interval prolonging medications and related drug-drug interactions in a cohort of psychiatry patients. Das B; Rawat VS; Ramasubbu SK; Kumar B Therapie; 2019 Dec; 74(6):599-609. PubMed ID: 31053339 [TBL] [Abstract][Full Text] [Related]
5. High prevalence of the risk factors for QT interval prolongation and associated drug-drug interactions in coronary care units. Khan Q; Ismail M; Haider I Postgrad Med; 2018 Nov; 130(8):660-665. PubMed ID: 30145917 [TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic Drug-Drug interactions of QT-prolonging drugs in hospitalized psychiatric patients. Hefner G; Hahn M; Hiemke C; Toto S; Wolff J; Roll SC; Klimke A J Neural Transm (Vienna); 2021 Feb; 128(2):243-252. PubMed ID: 33417009 [TBL] [Abstract][Full Text] [Related]
7. QT interval prolongation in hospitalized patients on cardiology wards: a prospective observational study. Khan Q; Ismail M; Haider I; Haq IU; Noor S Eur J Clin Pharmacol; 2017 Nov; 73(11):1511-1518. PubMed ID: 28803378 [TBL] [Abstract][Full Text] [Related]
8. Prevalence and Risk Factors Associated with Use of QT-Prolonging Drugs in Hospitalized Older People. Franchi C; Ardoino I; Rossio R; Nobili A; Biganzoli EM; Marengoni A; Marcucci M; Pasina L; Tettamanti M; Corrao S; Mannucci PM; Drugs Aging; 2016 Jan; 33(1):53-61. PubMed ID: 26693921 [TBL] [Abstract][Full Text] [Related]
9. Investigating the Additive Interaction of QT-Prolonging Drugs in Older People Using Claims Data. Meid AD; von Medem A; Heider D; Adler JB; Günster C; Seidling HM; Quinzler R; König HH; Haefeli WE Drug Saf; 2017 Feb; 40(2):133-144. PubMed ID: 27896662 [TBL] [Abstract][Full Text] [Related]
10. Leading 20 drug-drug interactions, polypharmacy, and analysis of the nature of risk factors due to QT interval prolonging drug use and potentially inappropriate psychotropic use in elderly psychiatry outpatients. Das B; Ramasubbu SK; Agnihotri A; Kumar B; Rawat VS Ther Adv Cardiovasc Dis; 2021; 15():17539447211058892. PubMed ID: 34841978 [TBL] [Abstract][Full Text] [Related]
11. Prevalence of QT-Prolonging Drug-Drug Interactions in Psychiatry: A Systematic Review and Meta Analysis. Ramasubbu SK; Mishra A; Mandal S J Pharm Pract; 2024 Feb; 37(1):162-168. PubMed ID: 35968552 [No Abstract] [Full Text] [Related]
13. Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT interval-prolonging drugs: a prospective, observational study in a large urban academic medical center in the US. Tisdale JE; Wroblewski HA; Overholser BR; Kingery JR; Trujillo TN; Kovacs RJ Drug Saf; 2012 Jun; 35(6):459-70. PubMed ID: 22612851 [TBL] [Abstract][Full Text] [Related]
14. Drug safety of macrolide and quinolone antibiotics in a tertiary care hospital: administration of interacting co-medication and QT prolongation. Niedrig D; Maechler S; Hoppe L; Corti N; Kovari H; Russmann S Eur J Clin Pharmacol; 2016 Jul; 72(7):859-67. PubMed ID: 27023463 [TBL] [Abstract][Full Text] [Related]
15. Frequency of use of QT-interval prolonging drugs in psychiatry in Belgium. Vandael E; Marynissen T; Reyntens J; Spriet I; Vandenberghe J; Willems R; Foulon V Int J Clin Pharm; 2014 Aug; 36(4):757-65. PubMed ID: 24805801 [TBL] [Abstract][Full Text] [Related]
16. Prevalence, Attributes, and Risk Factors of QT-Interval-Prolonging Drugs and Potential Drug-Drug Interactions in Cancer Patients: A Prospective Study in a Tertiary Care Hospital. Agnihotri A; Ramasubbu SK; Bandyopadhyay A; Bidarolli M; Nath UK; Das B Cureus; 2024 May; 16(5):e60492. PubMed ID: 38882995 [TBL] [Abstract][Full Text] [Related]
17. High prevalence of risk factors in elderly patients using drugs associated with acquired torsades de pointes chronically in Colombia. Moreno-Gutiérrez PA; Gaviria-Mendoza A; Cañón MM; Machado-Alba JE Br J Clin Pharmacol; 2016 Aug; 82(2):504-11. PubMed ID: 27060989 [TBL] [Abstract][Full Text] [Related]
18. Prevalence of QTc interval prolongation and its associated risk factors among psychiatric patients: a prospective observational study. Ali Z; Ismail M; Nazar Z; Khan F; Khan Q; Noor S BMC Psychiatry; 2020 Jun; 20(1):277. PubMed ID: 32493330 [TBL] [Abstract][Full Text] [Related]
19. [Drug-drug interactions with risk of QT-prolongation. A epidemiological study in Belgian community pharmacies]. Vandael E; De WuLf I; Foulon V J Pharm Belg; 2016 Dec; (4):14-23. PubMed ID: 30281244 [TBL] [Abstract][Full Text] [Related]
20. QTc Prolongation Associated With Psychiatric Medications: A Retrospective Cross-Sectional Study of Adult Inpatients. Shao W; Ayub S; Drutel R; Heise WC; Gerkin R J Clin Psychopharmacol; 2019; 39(1):72-77. PubMed ID: 30531476 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]